Pretty close to the mark it seems!
The most comprehensive study I can find on drug development probability of success (POS) is that only 13.8% of drugs entering Phase 1 make it to Approval. But this rises to 21% for drugs meeting Phase 1 endpoints and entering Phase 2. But for those that meet Phase 2 endpoints and enter Phase 3, the probability of approval rises to 59% - and that is Approval, not just success in Phase 3.
And if oncology drugs (which have a significantly lower POS) are omitted from the analysis, the success/approval rate from Phase 3 rises to a hefty 63.6%
https://academic.oup.com/biostatistics/article/20/2/273/4817524
So agree - given this relatively high rate of success from Phase 3 (almost 2 out of every 3) - together with the Advanz deal - it is indeed, an attractive 'punt'!
- Forums
- ASX - By Stock
- DXB
- DXB Chart
DXB Chart, page-375
-
- There are more pages in this discussion • 777 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
47.5¢ |
Change
-0.015(3.06%) |
Mkt cap ! $261.3M |
Open | High | Low | Value | Volume |
49.5¢ | 49.5¢ | 46.5¢ | $2.742M | 5.746M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 158396 | 47.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
48.0¢ | 162500 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 158396 | 0.475 |
7 | 184132 | 0.470 |
6 | 109327 | 0.465 |
10 | 226428 | 0.460 |
4 | 103472 | 0.455 |
Price($) | Vol. | No. |
---|---|---|
0.480 | 162500 | 2 |
0.485 | 31250 | 1 |
0.490 | 75153 | 3 |
0.495 | 86890 | 6 |
0.500 | 174085 | 5 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online